FDA concerns about Impax lab in Taiwan raise fears of fresh setback for Parkinson's drug; Galectin cites 'social media' for stock plunge;

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: I used to make fun of $PFE's big in-licensing deals (remember Medivation and Alzheimer's?) I'm switching to out-licensing now (neratinib). | Follow @JohnCFierce

@DamianFierce: Just wait until  finds out what people on Friendster are saying. More | Follow @DamianFierce

@EmilyMFierce: Ebola treatments caught in limbo. Nature piece | Follow @EmilyMFierce

> The FDA has raised concerns about Impax Lab's ($IPXL) manufacturing facility in Taiwan, sparking fears that it may further delay the biotech's Parkinson's drug Rytary, which was earlier held up by manufacturing woes in California. Story

> Shares of Galectin Therapeutics ($GALT) got hammered yesterday following a cohort analysis which it insists is positive. Today the biotech blamed "social media" for the meltdown, which included some harsh criticism. Release

Medical Device News

@FierceMedDev: Dental implant player Nobel Biocare is the latest med tech M&A target. Story | Follow @FierceMedDev

@StacyALawrence: Large healthcare customers squeeze med tech supplier Owens & Minor. Article | Follow @StacyALawrence

@VarunSaxena2: AcelRx discusses sublingual painkiller's rejection with concerned investors. FierceDrugDelivery article | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce

@EmilyWFierce: Epic Sciences ropes in $PFE and $RHHBY funding to commercialize CTC tests for cancer treatment. FierceDiagnostics story | Follow @EmilyWFierce

> Kickstarter in vogue as funding mechanism for new devices. Story

> What will changes to the Sunshine Act mean for devicemakers? Item

> Coloplast adding 150 jobs in the U.K. to boost chronic care business. Article

Pharma News

@FiercePharma: Popular on FiercePharmaMarketing: Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story | Follow @FiercePharma

@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. PR, ICYMI. Earnings statement (PDF) | Follow @TracyStaton

@EricPFierce: Hikma builds more heft in sterile manufacturing. Say it will take equipment out of closed Ben Venue plant. News | Follow @EricPFierce

@CarlyHFierce: Today in FiercePharmaMarketing: Doom for combo meds? PBMs dump 2-in-1 drugs; 'Name-calling' at FDA. Issue | Follow @CarlyHFierce

> Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts. Story

> A $635M win-win deal boosts Pfizer in vaccines, slims Baxter for spinoff. Article

> Amgen makes deep job cuts to position itself for post Enbrel-world. More

> Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebid. News

Drug Delivery News

> Amid fears of shortage of antibiotics, DNA origami technique developed to combat E. coli, other bugs. Article

> Nanoparticles deliver agents to spur immune system into action against cancer. Story

> Developer of unique delivery technology for eye care expanding in Europe. Item

> Nature-inspired artificial cilia could help move drugs to a target. More

> AcelRx discusses sublingual painkiller's rejection with concerned investors. Article

Diagnostics News

> In Q2, diagnostics venture investment showed some signs of life. More

> Epic Sciences' CTC cancer tests again draw Roche, Pfizer to investor table. Article

> Japan's Konica Minolta, New Jersey Dx outfit to develop heart attack rapid blood test. Story

> Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents. Article

> Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device. Item

Pharma Marketing News

> Doom for combo meds? Express Scripts, CVS dump Horizon Pharma two-in-one drugs. Report

> Name-calling: The FDA needs your ideas for locking down brand monikers. More

> AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits. More

> Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story

> Merck spokeswoman: Sales layoffs to hit PA-based field reps. Article